Bryte is a registered patent agent with more than 15 years of experience assisting pharma, biotech and materials science innovators to establish and develop global patent portfolios.
She particularly enjoys her early-stage clients where, as a part of a team that includes supervising attorneys, she characterizes the patent landscape and relevant prior art, ensures freedom to operate and crafts a strong theory of patentability to protect her client's inventions, all the while ensuring the patent pipeline is consonant with research and development.
Her foundational education in synthetic chemistry expands her competencies well beyond her core expertise with small molecule pharmaceuticals (and larger drug conjugates) to biotechnology (e.g., AAV engineering, gene therapy, antibody therapeutics, nucleotide vaccines), nuclear chemistry (nuclide generation, radiopharmaceuticals), nanotechnology (sensors, adhesives, cosmetics), polymer science (high performance, green), catalysts (zeolite, homogeneous), and semiconductors (single crystal Si, organic light emitting diodes).
Bryte's international life science practice includes obtaining mission-critical patents including those directed to second medical uses, personalized medicine (novelty is dosage regimes and patient selection), and more traditional methods of preventing, diagnosing and treating diseases in such indications as cancer, cardiovascular disease, genetic diseases, blood pathologies and autoimmune diseases.
Prior to joining Fenwick, Bryte worked for an AmLaw100 Firm and drafted applications based on clinical trial data, evergreened portfolios based on improved methods, formulations, and polymorphs, secured patents for Orange Book listed drug products, and expedited allowance through the use of Fast Track, AFP 2.0, global PPH, and gained experience drafting expert declarations, appeal briefs and petitions for patent term extension.
Bryte received her Ph.D. from Columbia University, where she studied the design and synthesis of small molecule organo-metallic enzyme mimics, which she characterized by, NMR, x-ray crystallography and computer modeling. While at Columbia, Bryte co-founded Women in Science at Columbia (WISC)—an organization dedicated to the outreach, support and advancement of women, underrepresented minorities and their advocates in the science, technology, engineering and mathematical graduate fields at the university. Bryte received her B.S., magna cum laude, from Virginia Polytechnic Institute and State University and was recognized for her achievement in undergraduate research synthesizing and characterizing DNA intercalators.
